Biochemically recurrent (BCR) prostate cancer is defined as a rising prostate specific antigen (PSA) [1] level in the absence of visible disease on imaging, such as conventional scans (CT and bone scan) and PET/CT scan (either Axumin PET/CT scan or PSMA PET/CT) [2,3]. This evidence concerns the gene KLK3 and prostate carcinoma.